title: Effects of initial combined tamsulosin and solifenacin therapy for overactive bladder and bladder outlet obstruction secondary to benign prostatic hyperplasia: a prospective, randomized, multicenter study.
abstract: OBJECTIVE
  The purpose of the study is to evaluate the clinical efficacy of initial combined therapy of an alpha-blocker and anticholinergic agent compared with the alpha-blocker alone in patients with benign prostatic hyperplasia (BPH) with overactive bladder (OAB).
  
  
  METHODS
  Hundred and fifty-six BPH patients with International Prostate Symptom Score (IPSS) of over 14 (voiding sub-score ≥ 8 and storage sub-score ≥ 6) were prospectively included in Korea. Group 1 (n = 69) was the patients who were treated with Tamsulosin 0.2 mg daily alone for 4 weeks and after 8 weeks they were treated with tamsulosin 0.2 mg and solifenacin 5.0 mg daily combination. Group 2 (n = 70) was the patients who were treated initially with tamsulosin 0.2 mg and solifenacin 5.0 mg combination for 12 weeks. Detailed questionnaires were used to assess treatment satisfaction at 4th week and at 12th week of treatment in 2 groups.
  
  
  RESULTS
  Baseline characteristics were not different between the 2 groups. In the 4th week, there was no difference between the 2 groups with regard to IPSS total score and voiding symptom score, although the IPSS storage symptom score was significantly lower in the Group 2 [-2.0 (0.2) △23.8 vs. -3.0 (0.2) △35.7] (P < 0.001). In the 12th week, there was improvement in storage indices such as IPSS storage symptom score, OABSS, and urgency symptoms compared with baseline in each group (P < 0.001). No statistical differences in storage indices observed between the two groups at 12 week.
  
  
  CONCLUSIONS
  Earlier treatment with alpha-blocker and anticholinergic agent helped to improve storage symptoms and quality-of-life scores earlier for patients with lower urinary tract symptoms related to BPH and OAB symptoms.
authors.affiliation: Department of Urology, Gangnam Severance Hospital, Yonsei University Health System, Seoul, Korea.
authors.forename: Seung Hwan
authors.initials: SH
authors.lastname: Lee
authors.forename: Seok Soo
authors.initials: SS
authors.lastname: Byun
authors.forename: Seung Ju
authors.initials: SJ
authors.lastname: Lee
authors.forename: Khae Hawn
authors.initials: KH
authors.lastname: Kim
authors.forename: Ji Youl
authors.initials: JY
authors.lastname: Lee
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D006801:Humans; D008297:Male; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000008:administration & dosage*; D011446:Prospective Studies; D011470:Prostatic Hyperplasia / Q000150:complications; D011812:Quinuclidines / Q000008:administration & dosage*; D000069464:Solifenacin Succinate; D013449:Sulfonamides / Q000008:administration & dosage*; D000077409:Tamsulosin; D044005:Tetrahydroisoquinolines / Q000008:administration & dosage*; D001748:Urinary Bladder Neck Obstruction / Q000188:drug therapy* / Q000209:etiology; D053201:Urinary Bladder, Overactive / Q000188:drug therapy*
chemical_list: D000317:Adrenergic alpha-Antagonists; D018727:Muscarinic Antagonists; D011812:Quinuclidines; D013449:Sulfonamides; D044005:Tetrahydroisoquinolines; D000077409:Tamsulosin; D000069464:Solifenacin Succinate